

News Release

February 4, 2020
Carna Biosciences, Inc.

Carna announces clearance of CTA to initiate clinical trial of AS-0871

Carna Biosciences, a biopharmaceutical company focusing on the discovery and development of innovative drugs targeting kinases, announces today that the Central Committee on Research Involving Human Subjects (CCMO) and the Ethics Committee have approved a Clinical Trial Application (CTA) for AS-0871, an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) with high selectivity targeting inflammatory and immune disorders. Carna expects to initiate a phase 1 study in healthy volunteers in the first half of 2020.

“We are pleased to receive an approval of CTA for AS-0871. We are proud that we can initiate our first-in-human study of AS-0871, produced by our talented drug discovery team,” said Kohichiro Yoshino, Ph.D., President and Chief Executive Officer at Carna Biosciences.

About AS-0871

Bruton's Tyrosine Kinase (BTK) is known to play a crucial role in multiple signaling pathways related to the immune responses in B-cells, macrophages, and mast cells, regulating the release of several proinflammatory mediators. The implication of BTK in a variety of pathological processes has been reported, and thus BTK has emerged as a promising target for inflammatory and immune disorders involving B-cell, macrophage, and mast cell activation. AS-0871 is a highly selective and non-covalent BTK inhibitor discovered by Carna, being developed for the treatment of inflammatory and immune disorders.

Contact:

Corporate Planning

Carna Biosciences, Inc.

TEL: +81-78-302-7075

<https://www.carnabio.com/english/>